Skip to main content
. 2012 Oct;19(10):1651–1660. doi: 10.1128/CVI.00258-12

Table 3.

Demographics and vaccination frequencies

Parametera Result for vaccine and dose (IU)
HVTN 040
HVTN 059
Placebo (n = 8) 1 × 104 (n = 20) 1 × 105 (n = 20) Total (n = 48) Placebo (n = 14) 1 × 105 (n = 20) 1 × 106 (n = 20) 1 × 107 (n = 20) 1 × 108 (n = 10) Total (n = 84)
Sex
    Male 4 (50%) 12 (60%) 9 (45%) 25 (52%) 9 (64%) 10 (50%) 13 (65%) 10 (50%) 5 (50%) 47 (56%)
    Female 4 (50%) 8 (40%) 11 (55%) 23 (48%) 5 (36%) 10 (50%) 7 (35%) 10 (50%) 5 (50%) 37 (44%)
Race
    White non-Hispanic 4 (50%) 7 (35%) 5 (25%) 16 (33%) 3 (21%) 10 (50%) 5 (25%) 9 (45%) 4 (40%) 31 (37%)
    Black/African American non-Hispanic 3 (38%) 12 (60%) 14 (70%) 29 (60%) 8 (57%) 10 (50%) 14 (70%) 11 (55%) 3 (30%) 46 (55%)
    Hispanic 1 (13%) 1 (5%) 0 (0%) 2 (4%) 2 (14%) 0 (0%) 0 (0%) 0 (0%) 3 (30%) 5 (6%)
    Native Hawaiian/Pacific Islander or multiracialb 0 (0%) 0 (0%) 1 (5%) 1 (2%) 1 (7%) 0 (0%) 1 (5%) 0 (0%) 0 (0%) 2 (2%)
Age (yr)
    18–20 1 (13%) 0 (0%) 1 (5%) 2 (4%) 1 (7%) 2 (10%) 0 (0%) 2 (10%) 0 (0%) 5 (6%)
    21–30 2 (25%) 9 (45%) 13 (65%) 24 (50%) 9 (64%) 10 (50%) 10 (50%) 8 (40%) 4 (40%) 41 (49%)
    31–40 1 (13%) 3 (15%) 2 (10%) 6 (13%) 3 (21%) 3 (15%) 4 (20%) 5 (25%) 2 (20%) 17 (20%)
    41–50 2 (25%) 7 (35%) 4 (20%) 13 (27%) 1 (7%) 5 (25%) 6 (30%) 5 (25%) 4 (40%) 21 (25%)
    Over 50 2 (25%) 1 (5%) 0 (0%) 3 (6%)
    Median 39.5 32.0 27.0 29.5 25.5 26.5 30.5 29.5 32.0 28.5
    Range 20–55 21–54 20–48 20–55 20–48 20–48 21–50 18–45 24–46 18–50
Vaccination frequencies
    Day 0 8 (100%) 20 (100%) 20 (100%) 48 (100%) 14 (100%) 20 (100%) 20 (100%) 20 (100%) 10 (100%) 84 (100%)
    Day 28 8 (100%) 19 (95%) 18 (90%) 45 (94%) 11 (79%) 20 (100%) 19 (95%) 12 (60%) 10 (100%) 72 (86%)
    Day 84 8 (100%) 18 (90%) 17 (85%) 43 (90%) 10 (71%) 20 (100%) 17 (85%) 10 (50%) 9 (90%) 66 (79%)
a

Results are no. (%) unless otherwise noted.

b

Data represent Native Hawaiian/Pacific Islander subjects for HVTN 040 and multiracial subjects for HVTN 059.